Hodgkin Disease/Lymphoma Clinical Practice Guidelines
Search for other papers by Memorial Sloan-Kettering Cancer Center in
Current site
Google Scholar
PubMed
Cure rates for Hodgkin disease/lymphoma have increased to such an extent that the overriding treatment considerations often relate to long-term toxicity, especially for patients with early- or intermediate-stage disease. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects.
For the most recent version of the guidelines, please visit NCCN.org
As the world's oldest and largest cancer center, Memorial Sloan-Kettering Cancer Center (MSKCC) is committed to exceptional patient care, leading-edge research, and superb educational programs. The close collaboration between its physicians and scientists is one of the Center's core strengths. At Sloan-Kettering Institute, state-of-the-art research flourishes side-by-side with clinical investigation and treatment at Memorial Hospital, the nation's oldest cancer hospital. An essential component of MSKCC's mission is education—training future clinicians and scientists and providing unique programs in the study of biomedical sciences to advance the standard of cancer care worldwide.
For more information, go to www.mskcc.org
© 2019-2024 National Comprehensive Cancer Network